Samsung Group market cap shrinks to 2022 levels
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
According to the Korea Exchange, Samsung Group stocks accounted for 27 percent of Kospi’s total market cap as of Sunday, down 3.97 percentage points from 30.97 percent at the beginning of 2024. This is a significant drop from the over 36 percent peak during the Covid-19 pandemic in March 2020, and is even lower than the 27.44 percent recorded in September 2022 when Samsung Electronics shares dipped to the low 50,000-won range.
The sharp decline in Samsung Group’s market cap is notable when compared to the overall market. While Kospi’s total market cap has only decreased by 1.37 percent in 2024 from 2,126.37 trillion won ($1,578 billion) to 2,097.29 trillion won, Samsung Group’s market cap plummeted by 13.84 percent from 657.2 trillion won to 566.24 trillion won.
Much of this decline can be attributed to the 22.8 percent drop in Samsung Electronics shares, Samsung Group’s largest constituent by market cap. Although Samsung Biologics, the group’s second-largest stock, has gained 31.45 percent in the year to date, it was not enough to offset the losses from Samsung Electronics.
All eyes are now on Samsung Electronics’ upcoming third-quarter earnings report, scheduled for October 8th, 2024, with market analysts divided on whether the results will help stabilize the stock. NH Investment & Securities analyst Kim Young-hwan warned that “the demand for DRAM, excluding high-bandwidth memory (HBM), and the average selling price (ASP) might fall short of market expectations, leading to potentially disappointing results.”
However, other analysts see a chance for a technical rebound. Samsung Electronics’ price-to-book ratio (PBR) for the next 12 months stood at 1.0 at the close of trading on October 4th, a level that was not seen even during the 2008 financial crisis. Daishin Securities analyst Lee Kyung-min emphasized that “whether Samsung Electronics’ operating profit exceeds 10 trillion won in the third quarter of 2024 is crucial.” He also noted that given the historically low valuation of South Korean semiconductors, the sector could be on the verge of a rebound.
While expectations for Samsung Electronics remain subdued, optimism surrounding Samsung Biologics is growing. Three securities firms raised their target prices for Samsung Biologics by up to 20 percent On October 4th, with KB Securities setting the highest target at 1.26 million won. Samsung Biologics’ stock closed at 999,000 won that day, just shy of the 1 million won mark. KB Securities pointed to growing inquiries related to contract development research in anticipation of the U.S. Biosecure Act being enacted later in the year, citing it as a key driver of the company’s long-term growth potential.
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- 구겨진 감자칩 봉투 펼쳤더니 ‘대반전’…200만원 넘는 지갑이었다 [영상] - 매일경제
- “여긴 벌써 겨울”…아파트 거래량 반토막 나고 매물은 쌓였다는데 - 매일경제
- “둘이 겁나 싸우던데”…지연 황재균 이혼에 네티즌 과거글 ‘재조명’ - 매일경제
- 오늘의 운세 2024년 10월 7일 月(음력 9월 5일) - 매일경제
- [단독] ‘만취운전’ 문다혜, 신호위반에 7시간 불법주차 의혹까지 - 매일경제
- “9급공무원 월급 알면서”...매달 10만원 모아 국장님 대접하는 ‘모시는 날’ 여전 - 매일경제
- 공포에 ‘바르르’ 떨던 소녀에 전세계가 속았다…구명보트 속 그녀 알고보니 - 매일경제
- 성실히 일하는 사람 바보 만드는 ‘퇴직 3종세트’ [매경데스크] - 매일경제
- 이재용, 필리핀서 삼성전기 ‘히든카드’ 챙겼다...올해 매출 1조원 목표라는데 - 매일경제
- 황인범 미쳤다! 9월 이달의 선수상→10월 데뷔골 폭발…페예노르트, 트벤테 꺾고 개막 7G 무패 행